Abstracts tagged "interferon"

Abstract Number: 1655 • ACR Convergence 2025
Aberrant Noncoding RNAs Are Enriched in Extracellular Vesicles and Implicated in Interferon Activation
Sandra Williams¹, Soyeong Sim² and Sandra Wolin², ¹National Institute of Arthritis, Musculoskeletal and Skin Diseases; National Cancer Institute, Bethesda, MD, ²National Cancer Institute, Frederick, MD
Background/Purpose: Extracellular vesicles (EVs) are small structures that enclose a variety of nucleic acids. While much of the published work on EV RNA has focused…
Abstract Number: 0617 • ACR Convergence 2025
Autoantibodies to Extracellular Antigens in Lupus Patients Serum Versus Controls; Predominance of Autoantibodies to Type I Interferons in Lupus Sera
Kathryn Counts¹, Dulaney Wilson², Leon Furchtgott³ and Gary Gilkeson¹, ¹Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, ³SeraNova Bio, Boston, MA
Background/Purpose: Key features in the pathophysiology of SLE include cytokine dysregulation and autoantibody production. Traditional autoantibody testing in SLE is primarily limited to intracellular antigens…
Abstract Number: 2418 • ACR Convergence 2025
ORF1p Expression Correlates with STING Activation and IFN Signatures in SLE Nonlesional Skin
Mehrnaz Gharaee-Kermani¹, Svenja Henning², John LaCava³, Tomas Mustelin⁴ and J. Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²University of Groningen, Groningen, Groningen, Netherlands, ³Rockefeller University, New York City, NY, NJ, ⁴University of Washington, Seattle, WA
Background/Purpose: Type I interferons (IFNs) are elevated in the skin and blood of patients with systemic (SLE) and cutaneous (CLE) lupus erythematosus. Upregulation of type…
Abstract Number: 1539 • ACR Convergence 2025
The Impact Of Interferon Signature On Anifrolumab Efficacy And Safety In Systemic Lupus Erythematosus: A Systematic Review And Meta-analysis
Muhammad Usman Hashmi¹, Paramarajan Piranavan², Yasmeen Sufi³, Zaira Nasir⁴, Zainab Azhar⁵, Shamaem Tariq⁵, Hamas Ul Hudaibia⁵, IMRAN SAEED⁶, Aayet Zulfiqar⁵, Natasha Rasool² and Anum Faiz⁷, ¹Rahmah Academy of Research Excellence, Islamabad, Pakistan., Islamabad, Pakistan, ²University of Kentucky, Louisville, KY, ³Karachi Medical & Dental College, Karachi, Karachi, Pakistan, ⁴Rawalpindi Medical University,Rawalpindi, Pakistan., Islamabad, Pakistan, ⁵Rawalpindi Medical University,Rawalpindi, Pakistan., Rawalpindi, Pakistan, ⁶Nishtar Medical University,Multan, Pakistan., Multan, Pakistan, ⁷Jinnah Hospital Lahore, Pakistan, Lahore, Pakistan
Background/Purpose: Type I interferon (IFN) signaling is central to systemic lupus erythematosus (SLE) pathogenesis, and anifrolumab, a monoclonal antibody targeting the IFN-α receptor (IFNAR), has…
Abstract Number: 0881 • ACR Convergence 2025
Circulating Monocytes with High Interferon Signature as Precursors to Osteopontin Expressing Lung Macrophages in Patients with Systemic Sclerosis and Progressive Interstitial Lung Disease
Shu-Ju Lin¹, Kimberly Taylor², Shen Yang³, Qinwei Chen⁴, Shehani Alexander¹, Ye Cao⁵, Takanori Sasaki⁵, Deepak Rao⁵, Nunzio Bottini⁶, Francesco Boin³ and Richard Ainsworth⁴, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²UC San Francisco, San Francisco, CA, ³Cedars-Sinai Medical Center, Beverly Hills, CA, ⁴Cedars Sinai Medical Center, Los Angeles, CA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Cedars Sinai Medical Center, Beverly Hills, CA
Background/Purpose: Circulating monocytes with pro-inflammatory and pro-fibrotic phenotype have been implicated in SSc-ILD pathogenesis, but their potential trajectory to mature cell lineage macrophages driving organ-specific…
Abstract Number: 2078 • ACR Convergence 2025
Neutrophil Extracellular Traps from Patients with Idiopathic Inflammatory Myopathies Induce Interferogenic Responses in Macrophages and Myeloid Dendritic Cells
Yatzil Reyna Juárez¹, Jennifer Tiaré Balderas Miranda², Beatriz Alcalá Carmona³, María José Ostos Prado⁴, karina santana⁵, Diana Gómez-Martín⁶ and Jiram Torres Ruiz⁷, ¹Instituto Politècnico Nacional, Tultitlán de Mariano Escobedo, Mexico State, Mexico, ²Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, ³INCMNSZ, Cdmx, Distrito Federal, Mexico, ⁴Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ⁵INCMNSZ, Ciudad de México, Federal District, Mexico, ⁶INCMNSZ, Mexico city, Federal District, Mexico, ⁷INCMNSZ, Mexico, Federal District, Mexico
Background/Purpose: Dermatomyositis (DM) and anti-synthetase syndrome (AS) are idiopathic inflammatory myopathies (IIM) with perifascicular pathology involving vasculopathy, macrophages, dendritic cells and an overexpression of interferon-stimulated…
Abstract Number: 1538 • ACR Convergence 2025
Safety, Pharmacodynamics, and Efficacy of a Novel Plasmacytoid Dendritic Cells Targeting Antibody in Healthy Adults and Patients with SLE or Cutaneous Lupus Erythematosus with Active Skin Lesions: A First-In-Human Study of KK4277
Minoru Hasegawa¹, Jun Kinoshita², Shigeki Otsubo³, Kana Yamada³ and Ehsanollah Esfandiari⁴, ¹Division of Medicine, University of Fukui, Yoshida-gun, Fukui, Japan, ²Kyowa Kirin Co., Ltd., Chiyoda-ku, Tokyo, Japan, ³Kyowa Kirin Co., Ltd., Tokyo, Japan, ⁴Kyowa kirin International plc, London, United Kingdom
Background/Purpose: Plasmacytoid dendritic cells (pDCs) are known to be the main source of type 1 interferon (IFN), which is the cause of various autoimmune diseases.…
Abstract Number: 0847 • ACR Convergence 2025
Interferon Score Effectively Stratifies for Time to Clinically Significant Event Accrual in Systemic Sclerosis Independently of Cutaneous Subset
Stefano Di Donato¹, Rebecca Ross², Marco Minerba³, Vishal Kakkar⁴, Enrico De Lorenzis⁵, Philip Yee⁶, Christopher Denton⁷ and Francesco Del Galdo⁴, ¹University of Leeds, Canosa Sannita, Chieti, Italy, ²Medicine and Health, University of Leeds, Leeds, United Kingdom, ³Campus Bio-Medico University of Rome, Taranto, Taranto, Italy, ⁴University of Leeds, Leeds, United Kingdom, ⁵Catholic University of the Sacred Heart, Roma, Rome, Italy, ⁶UCL, London, United Kingdom, ⁷University College London, UK, London, United Kingdom
Background/Purpose: Systemic Sclerosis (SSc) is a heterogeneous autoimmune disease characterized by vascular damage, immune dysregulation, and fibrosis. It is typically classified into limited cutaneous (lcSSc)…
Abstract Number: 1867 • ACR Convergence 2025
Deciphering the Molecular Landscape of the Small Intestine in Early and Late SSc Using High-Definition Spatial Transcriptomics
Laura Much¹, Elena Pachera², Havard Fretheim³, Knut EA Lundin⁴, Lumeng Li⁵, Astrid Hofman⁶, Pietro Bearzi⁵, Philip Stauffer¹, Michael Scharl⁷, Oyvind Molberg⁸, Oliver Distler⁹ and Anna-Maria Hoffmann-Vold³, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³Oslo University Hospital, Oslo, Norway, ⁴Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zürich, Switzerland, ⁶Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁷Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Oslo University Hospital, Oslo, Nepal, ⁹Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: SSc frequently results in serious gastrointestinal (GI) complications that contribute to increased morbidity and mortality. Understanding the molecular changes across different disease stages is…
Abstract Number: 1518 • ACR Convergence 2025
Efficacy and Safety of Anifrolumab in Discoid Lupus: A Meta-Analysis of the Literature
Ali Ali¹, Neelay Purohit², Ciji Robinson², Amanda Darzi³ and Alireza Meysami⁴, ¹Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System, Canton, MI, ²Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System, Detroit, MI, ³Department of Internal Medicine, Henry Ford Health System, Detroit, MI, ⁴Henry Ford Health, Detroit, MI
Background/Purpose: Anifrolumab, a monoclonal antibody targeting the type I interferon receptor, demonstrated clinical efficacy in systemic lupus erythematosus in the pivotal TULIP-2 trial¹. However, its…
Abstract Number: 0821 • ACR Convergence 2025
Flipping The Switch – Classical Complement Activation closely linked to IFN-signalling in Stills Disease
Freya Huijsmans¹, Alejandra Bodelón de Frutos¹, Lyanne Sijbers¹, Susanne Benseler², Joost Swart³, Rae Yeung⁴, Sebastiaan Vastert⁵ and Jorg van Loosdregt¹, ¹Pediatric Rheumatology & Immunology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, Utrecht, Netherlands, ²Cumming School of Medicine, Department of Pediatrics, University of Calgary, Calgary, AB, Canada, ³Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Utrecht, Netherlands, ⁴The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁵University Medical Center Utrecht, Utrecht, Utrecht, Netherlands
Background/Purpose: Stills disease (SD) is an autoinflammatory syndrome characterized by severe innate immune dysregulation. The complement system, an essential component of innate immunity, can drive…
Abstract Number: 1864 • ACR Convergence 2025
Mitochondrial Dysfunction Drives cGAS-STING–Mediated Type I Interferon Production and Fibrosis in Systemic Sclerosis
Giulio Forte¹, Vasiliki Liakouli¹, Alessia Salzillo², Mario Angeli³, Daniele Mauro¹, Antonio Ciancio¹, Barbara De Marino², Iacopo Panarese¹, Mario Faenza¹, roberto giacomelli⁴, Andreas Ramming⁵ and Francesco Ciccia⁶, ¹Università della Campania Luigi Vanvitelli, Naples, Italy, ²University of Campania L. Vanvitelli, Naples, Italy, ³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁴Università Campus Bio-Medico, Roma, Italy, ⁵Department of Internal Medicine ³, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany, ⁶Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, Italy
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by type I interferon (IFN-I) production and mitochondrial dysfunction. Emerging evidence suggests that activation of the…
Abstract Number: 1512 • ACR Convergence 2025
Anti-U1-RNP Antibody Positivity is Associated with Elevated Interferon Score in SLE Irrespective of Disease Activity: A Transcriptome Analysis in Japanese Patients
Takemichi Matsui¹, Yumi Tsuchida², Takahiro Itamiya², Mineto Ota², Toshihiko Komai², Haruka Tsuchiya², Hirofumi Shoda², Tomohisa Okamura² and Keishi Fujio², ¹Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Background/Purpose: With the introduction of anifrolumab to clinical practice, there is a growing interest in identifying factors associated with IFN activity in patients with SLE.…
Abstract Number: 0807 • ACR Convergence 2025
Deciphering Synovitis in Systemic Sclerosis
Celina Geiss¹, Miranda Houtman¹, Camino Calvo Cebrian¹, Raphael Micheroli², Melpomeni Toitou¹, Yannis Djeffal³, Alexandra Khmelevskaya¹, Mojca Frank-Bertoncelj¹, Sam Edalat¹, Thomas Rauer⁴, Kristina Bürki⁵, Chantal Pauli⁶, Michael Bonelli⁷, Thomas Karonitsch⁸, Oliver Distler⁹, Caroline Ospelt¹ and Muriel Elhai¹⁰, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Zurich, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³INSERM, IMRB, Université Paris Est Créteil, Paris, France, ⁴³Department of Traumatology, University Hospital Zurich, University of Zurich, Zurich, Zurich, Switzerland, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁶Institute for Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Zurich, Switzerland, ⁷Department of Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Wien, Austria, ⁸Department of Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁹Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ¹⁰University Hospital zurich, Zürich, Switzerland
Background/Purpose: Synovitis is a common manifestation of systemic sclerosis (SSc), driving disability and predicting disease progression and mortality. Current immunosuppressive strategies, largely extrapolated from rheumatoid…
Abstract Number: 1852 • ACR Convergence 2025
Cellular Landscape of Cutaneous Lupus Erythematosus Revealed by Single-Cell RNA Sequencing and Spatial Transcriptomics in the Lupus Accelerating Medicine Partnership Cohort
Victoria Werth¹, Jun Kang², Lais Lopes Almeida Gomes³, Christopher Richardson⁴, Benjamin Chong⁵, J. Michelle Kahlenberg⁶, Joel Guthridge⁷, Wade DeJager⁸, Susan Macwana⁷, Caleb Marlin⁷, Judith James⁷, Rachael Bogle⁹, Alex Tsoi⁹ and Johann Gudjonsson⁶, ¹University of Pennsylvania, Wynnewood, PA, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Rochester Medical Center, Rochester, NY, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶University of Michigan, Ann Arbor, MI, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Oklahoma Medical Research Foundation, Oklahoma City, ⁹University of Michigan, Holland, OH
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a chronic inflammatory skin disease associated with systemic lupus erythematosus (SLE) and characterized by a prominent type I interferon…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].